BNP PARIBAS ASSET MANAGEMENT Holding S.A. Buys 173,034 Shares of Boston Scientific Co. (NYSE:BSX)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in Boston Scientific Co. (NYSE:BSX) by 4.4% during the 3rd quarter, HoldingsChannel reports. The firm owned 4,119,399 shares of the medical equipment provider’s stock after acquiring an additional 173,034 shares during the quarter. Boston Scientific makes up approximately 0.9% of BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings, making the stock its 17th biggest holding. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in Boston Scientific were worth $345,205,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. BDF Gestion bought a new stake in Boston Scientific during the 2nd quarter worth approximately $3,570,000. LRI Investments LLC bought a new stake in Boston Scientific during the 1st quarter worth approximately $139,000. Cetera Advisor Networks LLC grew its position in Boston Scientific by 11.8% during the 1st quarter. Cetera Advisor Networks LLC now owns 201,426 shares of the medical equipment provider’s stock worth $13,796,000 after acquiring an additional 21,252 shares during the last quarter. Brookstone Capital Management grew its position in Boston Scientific by 389.1% during the 2nd quarter. Brookstone Capital Management now owns 69,945 shares of the medical equipment provider’s stock worth $5,414,000 after acquiring an additional 55,645 shares during the last quarter. Finally, HWG Holdings LP bought a new stake in Boston Scientific during the 2nd quarter worth approximately $482,000. 89.07% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on BSX shares. Royal Bank of Canada upped their price objective on Boston Scientific from $95.00 to $98.00 and gave the stock an “outperform” rating in a report on Thursday, October 24th. Truist Financial upped their price objective on Boston Scientific from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Barclays upped their price objective on Boston Scientific from $78.00 to $86.00 and gave the stock an “overweight” rating in a report on Thursday, August 22nd. Canaccord Genuity Group upped their price objective on Boston Scientific from $88.00 to $98.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Finally, Wells Fargo & Company upped their price objective on Boston Scientific from $87.00 to $98.00 and gave the stock an “overweight” rating in a report on Thursday, October 24th. Four analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $93.39.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $90.17 on Thursday. The company has a market capitalization of $132.90 billion, a PE ratio of 74.52, a PEG ratio of 2.56 and a beta of 0.79. Boston Scientific Co. has a 12 month low of $53.93 and a 12 month high of $91.08. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. The stock’s fifty day simple moving average is $85.71 and its 200 day simple moving average is $79.92.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 EPS for the quarter, topping the consensus estimate of $0.59 by $0.04. The business had revenue of $4.21 billion for the quarter, compared to the consensus estimate of $4.04 billion. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The firm’s revenue was up 19.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.50 EPS. On average, research analysts predict that Boston Scientific Co. will post 2.46 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Michael F. Mahoney sold 162,777 shares of the firm’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $84.63, for a total value of $13,775,817.51. Following the completion of the transaction, the chief executive officer now owns 1,572,096 shares in the company, valued at $133,046,484.48. This trade represents a 9.38 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Joseph Michael Fitzgerald sold 132,527 shares of the firm’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $85.00, for a total value of $11,264,795.00. Following the completion of the transaction, the executive vice president now owns 160,467 shares of the company’s stock, valued at $13,639,695. The trade was a 45.23 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 309,270 shares of company stock worth $26,196,718. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.